Figure 10.

Targeting integrin α_vβ₃specifically depletes CAPaSC in tumor. (A and B) Representative images of H&E staining (A) and pathologic assessment (B) of the tumors of GEM-KPC mice treated with vehicle or ProAgio. (C and D) Representative images of IHC staining of Ki67 (C), and quantitative analyses of Ki67-positive stain area (D) in tumor sections of vehicle or ProAgio-treated GEM-KPC mice. (E and F) Representative images of Oil red O staining (E) and quantitative analysis of Oil red O staining (F, Oil red⁺ area [fold], fold change by comparison with the mean value of the vehicle-treated group as 1) in tumor sections of GEM-KPC mice treated with the indicated agents (n = 4). (G and H) Representative images of co-staining of adipophilin (green) and cleaved PARP (red) (G), and quantification of adipophilin stain (H, adipophilin⁺ area [fold], fold change by comparison with the mean value of the vehicle treatment group as 1) in tumor sections of GEM-KPC treated with the indicated agents using ImageJ (n = 5). Image analysis was performed by thresholding for positive staining and normalizing to the total tissue area. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). (I) Schematic illustration of the mechanism depicting the action of ProAgio in PDAC tumor. (B, F, and H) Error bars represent means ± SEM. PARP, Poly (ADP-ribose) polymerase.